While AMT-130 could result in meaningful revenue for ClearPoint, the Huntington's opportunity is relatively modest compared ...

Universities must do more to provide students with cell and gene therapy manufacturing skills, according to a new study.

New data from Spherix Global Insights uncover how hematologists are defining the “right patient” for gene therapy, balancing promise with practical barriers in sickle cell disease, thalassemia, and ...

Takeda will step away from cell therapy in favour of biologics, small molecules and ADCs in a “strategic portfolio ...

Cirrus’ lead program is a novel AAV gene therapy designed to restore IRAK-M, a central regulator of the eye’s immune homeostasis, so as to ...

PHILADELPHIA, October 02, 2025--iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 6 presentations offering insights into the research and development of ...

Takeda is looking to offload its cell therapy platform and preclinical assets to a yet-unidentified external partner. 137 ...

Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA ...

French biotech EG 427 has had success with its urinary incontinence DNA therapy, EG110A, showing a more than 80% reduction in ...

Treatment introduces an expansion of the scope of gene therapies that might lead to similar treatments for neurodegenerative ...